Japan Approves Continued Use Of Strattera For AD/HD Patients Over 18
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare June 15 notified Eli Lilly's Japan subsidiary it expanded labeling for Strattera (atomoxetine), allowing the drug to be used continuously for patients over 18 years. Currently, Strattera is indicated for attention-deficit hyperactivity disorder for patients aged 6 to 18. However, the change only applies to patients who have started taking the drug before the age of 18 and need to continue the treatment. Eli Lilly is conducting a Phase III trial of Strattera on adult patients. Many AD/HD patients in Japan have expressed a desire to continue the medication even after they turn 18. (Click here for more - Japanese language)
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.